Bill > S2068

This bill aims to prohibit pharmaceutical companies from using direct-to-consumer advertising (DTCA) for prescription drugs across various media platforms. Specifically, the bill would amend the Federal Food, Drug, and Cosmetic Act to make a drug misbranded if its manufacturer has conducted any form of consumer-targeted promotional communication within the previous 30 days. DTCA is broadly defined to include advertisements through television, radio, print media, digital platforms, and social media. The prohibition would apply to all prescription drugs approved under section 505 of the Federal Food, Drug, and Cosmetic Act or licensed under section 351 of the Public Health Service Act, regardless of when the drug was originally approved. The amendment would take effect 30 days after the act's enactment, effectively banning pharmaceutical companies from directly marketing prescription medications to consumers through any media channel. This legislation seeks to reduce the influence of pharmaceutical marketing on patient-doctor interactions and potentially lower healthcare costs by limiting drug companies' ability to create demand for specific medications through widespread advertising.

Health and Social Services

https://www.congress.gov/bill/119th-congress/senate-bill/2068/all-info